Welcome to our dedicated page for Bone Biologics news (Ticker: BBLG), a resource for investors and traders seeking the latest updates and insights on Bone Biologics stock.
Bone Biologics Corp develops orthobiologic products for spine fusion markets, with its work centered on bone regeneration using the recombinant human protein rhNELL-1. Its lead product candidate, NB1, combines rhNELL-1 with demineralized bone matrix and is tied to the company’s focus on targeted bone regeneration in spinal fusion, with rights also noted for trauma and osteoporosis applications.
News about BBLG commonly covers clinical-development progress, product-readiness milestones such as rhNELL-1 shelf-life validation, patent activity, financing transactions, Nasdaq listing compliance, and corporate updates on scientific and operational priorities.
Bone Biologics Corp. (NASDAQ: BBLG) announced the pricing of its public offering of 1,510,455 units at $5.25 each, raising gross proceeds of approximately $7.9 million. Each unit comprises one share of common stock and one warrant to buy a share at $6.30, expiring in five years. The offering, effective October 15, 2021, follows a 1-for-2.5 reverse stock split executed on October 12, 2021. Underwriters may purchase an additional 226,568 shares for overallotments. Trading began on October 13, 2021. WallachBeth Capital is the book-running manager.